2 months Should Bristol Myers Stock Be in Your Portfolio Pre-Q3 Earnings? Zacks
BMY is looking to turnaround its business, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well for the stock, and we recommend it to investors.
Biotech · Bristol · Bristol-Myers Squibb (BMY) · Earnings
X